Absence of Somatic MYD88 L265P Mutations in Patients with Primary Sjogren's Syndrome

Overview

Journal Genes Immun

Date 2013 Oct 25

PMID 24153350

Citations 2

Authors

M Voulgarelis

C P Mavragani

L Xu

S P Treon

H M Moutsopoulos

Affiliations

Soon will be listed here.

Abstract

Sjogren's syndrome (SS) is a chronic autoimmune disorder with the highest risk for lymphoma development among all autoimmune diseases. In order to evaluate whether the presence of the recently described MYD88 L265P mutation in patients with Waldenström's macroglobulinemia (WM) is contributory to SS-associated lymphomagenesis, a quantitative allele-specific PCR method was performed in peripheral blood derived from 90 SS patients as well as in minor salivary gland tissues derived from 12 primary SS patients with or without lymphoma. MYD88 L265P was not detected in either of the samples tested. Although the absence of the MyD88 L265P somatic mutation in our SS cohort does not exclude a common germline susceptibility gene in SS, it might suggest a distinct operating pathogenetic mechanism in SS-related lymphoma compared with WM and other hematological malignancies.

Citing Articles

Pathogenetic Mechanisms Implicated in Sjögren's Syndrome Lymphomagenesis: A Review of the Literature.

Stergiou I, Poulaki A, Voulgarelis M J Clin Med. 2020; 9(12).

PMID: 33255258 PMC: 7759999. DOI: 10.3390/jcm9123794.

Contribution of Genetic Factors to Sjögren's Syndrome and Sjögren's Syndrome Related Lymphomagenesis.

Nezos A, Mavragani C J Immunol Res. 2015; 2015:754825.

PMID: 26550578 PMC: 4624885. DOI: 10.1155/2015/754825.

References

Xu L, Hunter Z, Yang G, Zhou Y, Cao Y, Liu X . MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013; 121(11):2051-8. PMC: 3596964. DOI: 10.1182/blood-2012-09-454355. View

Voulgarelis M, Ziakas P, Papageorgiou A, Baimpa E, Tzioufas A, Moutsopoulos H . Prognosis and outcome of non-Hodgkin lymphoma in primary Sjögren syndrome. Medicine (Baltimore). 2011; 91(1):1-9. DOI: 10.1097/MD.0b013e31824125e4. View

Quartuccio L, Salvin S, Fabris M, Maset M, Pontarini E, Isola M . BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology (Oxford). 2012; 52(2):276-81. DOI: 10.1093/rheumatology/kes180. View

Rawlings D, Schwartz M, Jackson S, Meyer-Bahlburg A . Integration of B cell responses through Toll-like receptors and antigen receptors. Nat Rev Immunol. 2012; 12(4):282-94. PMC: 3437941. DOI: 10.1038/nri3190. View

Zintzaras E, Voulgarelis M, Moutsopoulos H . The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 2005; 165(20):2337-44. DOI: 10.1001/archinte.165.20.2337. View

Ngo V, Young R, Schmitz R, Jhavar S, Xiao W, Lim K . Oncogenically active MYD88 mutations in human lymphoma. Nature. 2010; 470(7332):115-9. PMC: 5024568. DOI: 10.1038/nature09671. View

Sisto M, Lisi S, Lofrumento D, Ingravallo G, De Lucro R, DAmore M . Salivary gland expression level of IκBα regulatory protein in Sjögren's syndrome. J Mol Histol. 2013; 44(4):447-54. DOI: 10.1007/s10735-013-9487-6. View

Mavragani C, Crow M . Activation of the type I interferon pathway in primary Sjogren's syndrome. J Autoimmun. 2010; 35(3):225-31. DOI: 10.1016/j.jaut.2010.06.012. View

Leadbetter E, Rifkin I, Hohlbaum A, Beaudette B, Shlomchik M, Marshak-Rothstein A . Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature. 2002; 416(6881):603-7. DOI: 10.1038/416603a. View

10.

Vitali C, Bombardieri S, Jonsson R, Moutsopoulos H, Alexander E, Carsons S . Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002; 61(6):554-8. PMC: 1754137. DOI: 10.1136/ard.61.6.554. View

11.

Manoussakis M, Boiu S, Korkolopoulou P, Kapsogeorgou E, Kavantzas N, Ziakas P . Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjögren's syndrome: correlation with certain features of immune hyperactivity and factors associated.... Arthritis Rheum. 2007; 56(12):3977-88. DOI: 10.1002/art.23073. View

12.

Kristinsson S, Koshiol J, Bjorkholm M, Goldin L, McMaster M, Turesson I . Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia. J Natl Cancer Inst. 2010; 102(8):557-67. PMC: 2857799. DOI: 10.1093/jnci/djq043. View

13.

Nezos A, Papageorgiou A, Fragoulis G, Ioakeimidis D, Koutsilieris M, Tzioufas A . B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome. J Autoimmun. 2013; 51:89-98. DOI: 10.1016/j.jaut.2013.04.005. View

14.

Treon S, Xu L, Yang G, Zhou Y, Liu X, Cao Y . MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med. 2012; 367(9):826-33. DOI: 10.1056/NEJMoa1200710. View

15.

Voulgarelis M, Skopouli F . Clinical, immunologic, and molecular factors predicting lymphoma development in Sjogren's syndrome patients. Clin Rev Allergy Immunol. 2007; 32(3):265-74. DOI: 10.1007/s12016-007-8001-x. View

16.

Theander E, Vasaitis L, Baecklund E, Nordmark G, Warfvinge G, Liedholm R . Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome. Ann Rheum Dis. 2011; 70(8):1363-8. PMC: 3128323. DOI: 10.1136/ard.2010.144782. View